Bonilla Francisco A
Division of Immunology, Children's Hospital Boston, Fegan Building, 6th Floor, 300 Longwood Avenue, Boston, MA 02115, USA.
Immunol Allergy Clin North Am. 2008 Nov;28(4):803-19, ix. doi: 10.1016/j.iac.2008.06.006.
This article reviews pharmacokinetic studies of IgG administration by intravenous and subcutaneous routes. Intravenous immunoglobulin pharmacokinetics have been studied during replacement therapy for primary and secondary immunodeficiencies and other special circumstances (eg, infection prophylaxis in neonates). Subcutaneous immunoglobulin pharmacokinetics have been studied only during replacement therapy for primary immunodeficiency. Published studies vary greatly with respect to the nature of the patients studied, dose regimens, sampling schedules, and pharmacokinetic models, making comparisons difficult. With either route of administration, there is large variation in individual IgG elimination rates. Periodic measurement of serum IgG concentration is critical to monitor the adequacy of replacement during therapy.
本文综述了静脉和皮下途径给予免疫球蛋白（IgG）的药代动力学研究。静脉注射免疫球蛋白的药代动力学已在原发性和继发性免疫缺陷的替代治疗以及其他特殊情况（如新生儿感染预防）中进行了研究。皮下免疫球蛋白的药代动力学仅在原发性免疫缺陷的替代治疗期间进行了研究。已发表的研究在研究对象的性质、给药方案、采样时间表和药代动力学模型方面差异很大，难以进行比较。无论采用哪种给药途径，个体IgG消除率都有很大差异。定期测量血清IgG浓度对于监测治疗期间替代治疗的充分性至关重要。
